Indication

Diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma is an aggressive malignancy of the lymphatic system and the most common subtype of non-Hodgkin lymphoma, predominantly affecting older adults. Read more about Diffuse large B-cell lymphoma

242 drugs 143 manufacturers

Advertisement

Drugs that treat it

Common Diffuse large B-cell lymphoma therapies.

Showing 91–99 of 242 drugs

CYCLOPHOSPHAMIDE

NITROGEN MUSTARD DERIVATIVES·RETINOBLASTOMA·+17
AMERIGEN PHARMA

CYCLOPHOSPHAMIDE

NITROGEN MUSTARD DERIVATIVES·RETINOBLASTOMA·+17
STI PHARMA, LLC

DEXAMETHASONE

GLUCOCORTICOSTEROIDS·DISSEMINATED TUBERCULOSIS·+61
FERA PHARMACEUT
Filter & compare in the drug finder →Opens the drug finder with Diffuse large B-cell lymphoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma is an aggressive malignancy of the lymphatic system and the most common subtype of non-Hodgkin lymphoma, predominantly affecting older adults.

It arises from mature B lymphocytes at various stages of differentiation, most notably classified by cell of origin into germinal center B-cell-like and activated B-cell-like phenotypes.

Pathophysiologically, it is characterized by the diffuse proliferation of abnormally large B cells that obliterate normal lymph node architecture or infiltrate extranodal sites.

Clinically, patients typically present with rapidly enlarging nodal or extranodal masses, which may be accompanied by constitutional B symptoms such as fever, drenching night sweats, and unintentional weight loss.

Personalize your experience

Follow Diffuse large B-cell lymphoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it